Conjunctivitis: A Systematic Review by A. Azari, Amir & Arabi, Amir
Review Article
Conjunctivitis: A Systematic Review
Amir A. Azari, MD1,2, Amir Arabi, MD, MPH1,2
1Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
2Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
ORCID:
Amir A. Azari: https://orcid.org/0000-0003-2013-3284
Abstract
Conjunctivitis is a commonly encountered condition in ophthalmology clinics throughout
the world. In the management of suspected cases of conjunctivitis, alarming signs for
more serious intraocular conditions, such as severe pain, decreased vision, and painful
pupillary reaction, must be considered. Additionally, a thorough medical and ophthalmic
history should be obtained and a thorough physical examination should be done in
patients with atypical findings and chronic course. Concurrent physical exam findings
with relevant history may reveal the presence of a systemic condition with involvement
of the conjunctiva. Viral conjunctivitis remains to be the most common overall cause of
conjunctivitis. Bacterial conjunctivitis is encountered less frequently and it is the second
most common cause of infectious conjunctivitis. Allergic conjunctivitis is encountered
in nearly half of the population and the findings include itching, mucoid discharge,
chemosis, and eyelid edema. Long-term usage of eye drops with preservatives in a
patient with conjunctival irritation and discharge points to the toxic conjunctivitis as the
underlying etiology. Effective management of conjunctivitis includes timely diagnosis,
appropriate differentiation of the various etiologies, and appropriate treatment.
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INTRODUCTION
Conjunctivitis is characterized by inflammation and
swelling of the conjunctival tissue, accompanied
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by engorgement of the blood vessels, ocular
discharge, and pain. Many subjects are affected
with conjunctivitis worldwide, and it is one of
the most frequent reasons for office visits to
general medical and ophthalmology clinics. More
than 80% of all acute cases of conjunctivitis are
reported to be diagnosed by non-ophthalmologists
including internists, family medicine physicians,
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pediatricians, and nurse practitioners.[1]
This imposes a great economic burden
to the healthcare system and occupies a
great proportion of the office visits in many
medical specialties. It is estimated that the
cost of treating bacterial conjunctivitis is
$857 million annually in the United States
alone.[2]
It has been reported that nearly 60% of
all patients with acute conjunctivitis receive
antibiotic eye drops; and the vast majority receive
their prescription from a non-ophthalmologist
physician. For example, 68% of patients
who visited a physician at an emergency
room received antibiotic eye drops while this
figure dropped to 36% for those who saw an
ophthalmologist.[1] Interestingly, patients from
a higher socioeconomic status were more
likely to receive and fill a prescription for their
conjunctivitis.[1]
There are several ways to categorize
conjunctivitis; it may be classified based on
etiology, chronicity, severity, and extend of
involvement of the surrounding tissue. The
etiology of conjunctivitis may be infectious or
non-infectious. Viral conjunctivitis followed by
bacterial conjunctivitis is the most common
cause of infectious conjunctivitis, while allergic
and toxin-induced conjunctivitis are among
the most common non-infectious etiologies.
In terms of chronicity, conjunctivitis may
be divided into acute with rapid onset and
duration of four weeks or less, subacute, and
chronic with duration longer than four weeks.[3]
Furthermore, conjunctivitis may be labeled
as severe when the affected individuals are
extremely symptomatic and there is an abundance
of mucopurulent discharge. Conjunctivitis may
be associated with the involvement of the
surrounding tissue such as the eyelid margins
and cornea in blepharoconjunctivitis and viral
keratoconjunctivitis, respectively.
Additionally, conjunctivitis may be associated
with systemic conditions, including immune-
related diseases [e.g., Reiter’s, Stevens-Johnson
syndrome (SJS), and keratoconjunctivitis
sicca in rheumatoid arthritis], nutritional
deprivation (vitamin A deficiency), and
congenital metabolic syndromes (Richner-
Hanhart syndrome and porphyria)[4, 5] (Table
1).
It is extremely important to differentiate
conjunctivitis from other causes of “red eye”
associated with severe sight- or life-threatening
consequences such as acute angle closure
glaucoma, uveitis, endophthalmitis, carotid-
cavernous fistula, cellulitis, and anterior segment
tumors.
METHODS
The scientific literature published as of
February 2020 was thoroughly reviewed by
searching PubMed, the ISI web of knowledge
database, and the Cochrane library using
relevant keywords. The following keywords
were used: ”bacterial conjunctivitis”, ”viral
conjunctivitis,” ”allergic conjunctivitis”, ”treatment
of bacterial conjunctivitis”, and ”treatment of
viral conjunctivitis”. No language restriction was
applied.
Articles published between March 2013 and
February 2020 were screened and those that
provided the best evidence-based information
were included in this review. A total of 167 articles
were finally included. The first study was published
in 1964 and the last study was published in 2020.
History and clinical examination
How to diagnose conjunctivitis
Conjunctival injection or “red eye” is a shared
presentation for many ophthalmic diseases,
and it accounts for up to 1% of all primary
care office visits.[6] The clinicians, whether
ophthalmologist or not, must be aware that “red
eye” may be the presenting sign for serious
eye conditions such as uveitis, keratitis, or
scleritis, or it may be secondary to more benign
conditions that are limited just to the conjunctival
tissue (e.g., conjunctivitis or subconjunctival
hemorrhage). Traditionally, it was believed that
more harmful ophthalmic disorders are associated
with disturbances in vision, disabling pain, and
photophobia.[6] However, in a recent large meta-
analysis,[6] anisocoria and mild photophobia
were significantly associated with “serious
eye conditions”; the presence of these two
signs could discover 59% of cases of “serious
eye conditions”, including anterior uveitis and
keratitis. Table 2 provides a summary of the
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Table 1. Guideline to help differentiate the major etiologies in conjunctivitis
Clinical history and exam findings Most probable etiologies
Alarming signs and symptoms
Decreased vision, severe pain, painful pupillary reaction,
anisocoria, orbital signs
Uveitis, scleritis, keratitis, glaucoma, orbital, or parasellar
pathology
Chronicity
Sudden onset, lasting less than four weeks Infectious conjunctivitis, allergic conjunctivitis, acute systemic
reactions (SJS/TEN)
Insidious onset, chronic course Conjunctivitis associated with systemic diseases, toxic
conjunctivitis, allergic conjunctivitis
Recurrent course Allergic conjunctivitis, conjunctivitis associated with systemic
diseases
Associated symptoms
Skin lesions, arthropathy, genito-perineal involvement,
oropharyngeal lesions
Conjunctivitis associated with systemic diseases, infectious
diseases
Drug history
Long-term eye drop usage Toxic conjunctivitis, allergic conjunctivitis
Recent initiation of a systemic medication Acute systemic reactions (SJS/TEN)
SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis
main etiologies of “red eye” and their clinical
characteristics.
How to distinguish infectious conjunctivitis
from non-infectious conjunctivitis
Obtaining history from patients who present
with conjunctivitis is crucial in order to arrive
at the correct diagnosis. A focused ocular
history should include the following: onset and
duration of symptoms; laterality; impairment of
vision; presence of itching; contact lens wear
history; presence of fellow travelers such as
recent upper respiratory infection, sinusitis,
and lymphadenopathy; previous episodes of
conjunctivitis; systemic allergies and medication;
and history of exposure to chemical agents.
The presence of constitutional signs such
as fever, malaise, fatigue, and contact with
individuals with conjunctivitis helps to further
narrow down the differential diagnosis. Physical
examination, including checking for palpable
lymph nodes, especially in the periauricular and
submandibular areas, is of great importance.
Ophthalmic examination should be performed
to determine the type of discharge. Closer
examination using a slit-lamp biomicroscope
to evaluate the ocular surface structures including
the palpebral conjunctiva for the presence of
pseudomembranes, symblepharon, papilla or
follicles, and the corneal tissue for the presence of
opacities and infiltrates is absolutely essential.
Some of the clinical signs and symptoms that
are used to help diagnose infectious conjunctivitis
include the following: eye discharge, conjunctival
injection, presence of red eye(s), eyelashes being
stuck together in the morning, grittiness of the
eye(s), eyelid or conjunctival edema, and history of
contact with individuals with conjunctivitis.[7]
Allergic conjunctivitis may be underdiagnosed
and undertreated.[8] It is presented with itching,
chemosis, and redness in the absence of any
significant corneal involvement.[9] The degree of
conjunctival swelling is often out of proportion
to conjunctival hyperemia. The main findings in
vernal keratoconjunctivitis (VKC) are the presence
of giant papillae in the superior tarsal conjunctiva
accompanied by severe itching,[10] while the
presence of conjunctival scar and anterior
subcapsular cataract supports the diagnosis
of atopic keratoconjunctivitis (AKC).[11]
Another similar condition, chronic toxic
conjunctivitis, may present with watery discharge,
an initial papillary conjunctival reaction followed by
a follicular reaction, punctate epithelial erosion of
the cornea, and eyelid dermatitis.[12–14]
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Table 2. Selected non-conjunctivitis etiologies of red eye
Differential diagnosis Symptoms Exam findings
Dry eyes Burning and FB sensation. Symptoms are
usually transient, worse with reading or
watching TV due to decreased blinking.
Symptoms are worse in dry, cold, and
windy environments due to increased
evaporation
Bilateral redness, superficial punctate
keratopathy, meibomian glands
dysfunction, decreased tear break-up
time, small tear meniscus
Blepharitis Similar to dry eyes Redness greater at the margins of eyelids,
inflammation, telangiectasia, and crust
around eyelashes
Pterygium Recurrent ocular redness Visible conjunctival extension over the
cornea
Hordeolum, chalazion Eyelid pain and swelling Palpable eyelid mass, may be tender or
not
Anterior segment tumors Variable Variable
Corneal abrasion, keratitis, corneal foreign
body
FB sensation, relevant history including
contact lens usage and occupational
exposure
Corneal epithelial defects, corneal
infiltration, corneal FB
Contact lens overwear Relevant history Corneal epithelial defect
Subconjunctival hemorrhage Ocular redness Blood under conjunctiva
Scleritis Decreased vision, moderate to severe
pain
Redness, bluish scleral hue
Iritis Photophobia, pain, blurred vision.
Symptoms are usually bilateral
Decreased vision, poorly reacting pupils,
constant eye pain radiating to temple and
brow. Redness, severe photophobia,
presence of inflammatory cells in the
anterior chamber
Angle closure glaucoma Headaches, nausea, vomiting, ocular
pain, decreased vision, light sensitivity,
and seeing haloes around lights.
Symptoms are usually unilateral.
Firm eye upon palpation, ocular redness
with limbal injection. Appearance of a
hazy/steamy cornea, moderately dilated
pupils that are unreactive to light.
Carotid cavernous fistula Chronic red eye, may have a history of
head trauma
Dilated tortuous vessels (corkscrew
vessels), bruits upon auscultation with a
stethoscope
Endophthalmitis Severe pain, photophobia, may have a
history of eye surgery or ocular trauma
Redness, puss in the anterior chamber
and photophobia
Cellulitis Pain, double vision, and fullness Redness and swelling of lids, may have
restriction of the eye movements, may
have a history of preceding sinusitis
(usually ethmoiditis)
FB, foreign body; TV, television
How to distinguish bacterial conjunctivitis
from viral conjunctivitis
Predicting the underlying etiology of conjunctivitis
based on the presenting signs and symptoms
may often result in an inaccurate diagnosis. In
one study, centers with expertise in ocular surface
disease had an accuracy rate of only 48% inmaking
the correct diagnosis of adenoviral conjunctivitis.[15]
Several other studies demonstrated that bacterial
pathogens are only isolated in 50% of cases of
suspected bacterial conjunctivitis.[16] In addition,
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one study reported that up to 52% of presumed
cases of viral conjunctivitis were culture-positive for
bacteria.[15]
Traditionally, the following associations between
the clinical history and the etiology of conjunctivitis
were believed to be true; these principles were
presented in many textbooks and were used
to select patients in many clinical trials.[17] For
example, according to the major text books
in ophthalmology (e.g., Krachmer, Duane, and
Kanski), involvement of one eye followed by the
involvement of the second eye within 24–48
hours is indicative of bacterial infection, while if
the second eye becomes infected after 48 hours
with an accompanying enlarged periauricular
lymph node, a viral etiology should be considered.
According to the same textbooks, a papillary
conjunctival reaction or pseudomembranous
conjunctivitis strongly suggests a bacterial origin
for conjunctivitis while follicular conjunctival
reaction is more likely to indicate a viral etiology.
There are many other associations between the
etiology of conjunctivitis and symptoms that are
thought to be true, but lack strong clinical evidence.
For example, association between lack of itching
and bacterial conjunctivitis have come under
scrutiny in the recent years. Other associations
that once thought to be true but lack evidence
include: recent upper respiratory tract infection and
lymphadenopathy in favor of viral conjunctivitis;
sinusitis, fever, malaise, and fatigue in association
with bacterial conjunctivitis; and previous history
of conjunctivitis with bilateral involvement of the
eyes in favor of viral and allergic but not bacterial
conjunctivitis.
A meta-analysis in 2003 failed to find any
clinical studies correlating the signs and symptoms
of conjunctivitis with its underlying etiology.[17]
Following the above meta-analysis, a prospective
study was conducted and found that combination
of three signs, bilateral mattering of the eyelids,
lack of itching, and no previous history of
conjunctivitis were strong predictors of bacterial
conjunctivitis.[18] Having both eyes matter and
their eyelashes adhere together in the morning
was a stronger predictor for positive bacterial
culture, and either itching or a previous episode of
conjunctivitis made a positive bacterial culture less
likely. In addition, types of the discharge (purulent,
mucus, or watery) or other symptoms were not
specific to any particular class of conjunctivitis.
A more recent meta-analysis, which analyzed
the clinical data of 622 patients from three clinical
trials,[19] found that patients with purulent discharge
or mild to moderate red eye were less likely
to benefit from topical antibiotics; this finding
reiterates lack of meaningful correlation between
signs and symptoms and the underlying etiology
in most cases of conjunctivitis. Another recent
study in 2013 found a strong likelihood of positive
bacterial culture results in patients with the “gluing
of the eyelids” upon waking up in the morning, and
the age above 50 at presentation.[20]
How do laboratory findings help us?
Clinicians may collect discharge samples from
eyes with conjunctivitis and send them for
microbiological evaluation. Conjunctival cultures
are generally reserved for cases of suspected
infectious neonatal conjunctivitis, recurrent
conjunctivitis, conjunctivitis recalcitrant to therapy,
conjunctivitis presenting with severe purulent
discharge, and cases suspicious for gonococcal or
chlamydial infection.[21] Swabs from the discharge
are better to be taken before the initiation of
antimicrobial therapy. The swabs are then plated
in various growth mediums in the laboratory for
obtaining cultures. Sabouraud agar plates are
used to identify fungus, and it should be utilized
in patients with chronic blepharitis and those
who are immunocompromised. Anaerobic culture
plates may also be helpful, especially in patients
with a history of previous surgery or trauma.[22] If
antimicrobial therapy has already been started,
they should be stopped 48 hours prior to obtaining
cultures. In a five-year review of 138 pediatric ocular
surface infections, the most common organisms
were coagulase-negative staphylococci, followed
by Pseudomonas aeruginosa and Staphylococcus
aureus.[23]
Nucleic acid amplification techniques, requiring
special swabs, may be used in diagnosing viral
infections, where a multitude of polymerase chain
reaction (PCR) tests for detection of viruses are
available.
Although primary studies from in-office rapid
antigen testing for adenoviruses report 89%
sensitivity and up to 94% specificity,[21] the results of
more recent studies point toward a high specificity
but only moderate sensitivity ranging from 39.5%
to 50%.[24] Accordingly, it may be suggested
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that negative Adeno-Plus test results should be
confirmed by real-time PCR owing to its suboptimal
sensitivity.
For those suspected of having allergic
conjunctivitis, skin scratch test or intradermal
injection of common allergens, and assays for
detecting elevated in vitro levels of specific serum
IgE may be used; however, the diagnosis of allergic
conjunctivitis remains a clinical one.
Viral conjunctivitis
Viral conjunctivitis is the most common overall
cause of infectious conjunctivitis, and it is usually
secondary to inoculation of the ocular surface
with the adenoviruses.[25, 26] Less frequently, other
viruses may be the underlying etiology in viral
conjunctivitis; amongst them, herpes simplex virus
(HSV), varicella zoster virus (VZV), and enterovirus
have been the subject of investigation.[27]
Adenoviral conjunctivitis
As the leading cause of infectious conjunctivitis
worldwide, up to 90% of viral conjunctivitis cases
are caused by adenoviruses.[28] Recent advances
in genome sequencing of human adenoviruses
(HAdV) have identified over 72 unique HAdV
genotypes classified into seven different species
(HAdV-A through HAdV-G), with HAdV-D species
having the most members and the strongest
association with viral conjunctivitis.[29, 30]
Perhaps the most common form of
infection by the adenoviruses in children is
pharyngoconjunctival fever (PCF) caused by
HAdV types 3, 4, and 7.[31–33] This condition is
usually characterized by the presence of fever,
pharyngitis, periauricular lymphadenopathy, and
acute follicular conjunctivitis. Additional ocular
surface findings include edema, hyperemia, and
petechial hemorrhages of the conjunctiva as a
result of interaction between pro-inflammatory
cytokines and conjunctival vasculature.[32]
This condition is self-limited, often resolving
spontaneously in two–three weeks without any
treatment.
The most severe ocular manifestation
of adenoviral infection is the epidemic
keratoconjunctivitis (EKC); this condition affects
both the conjunctiva and cornea, leaving behind
long-lasting and permanent ocular surface
changes and visual disturbances. Ocular
manifestations of EKC include conjunctival
discharge, follicular conjunctivitis, corneal
subepithelial infiltrates (SEI), corneal scarring,
development of conjunctival membranes and
pseudomembranes, and symblepharon formation
(Figures 1 and 2).
Classically, serotypes 8, 19, 37, and less
frequently serotype 4 were believed to be
associated with EKC, but more recently, HAdV-D53
and HAdV-D54 have been identified in several
outbreaks and are thought to be responsible for
the majority of EKC cases.[30]
Pseudomembranes, which are sheets of fibrin-
rich exudates without blood or lymphatic vessels,
may be encountered in the tarsal conjunctiva of
the EKC patients.[35] Depending on the intensity
of inflammation, true conjunctival membranes may
also form in EKC. True membranes, once form, can
lead to the development of subepithelial fibrosis
and symblepharon; additionally, they tend to bleed
severely upon removal.[36]
Cornea is another tissue that may become
adversely affected in EKC. Replication of the virus
in the corneal epithelium may cause superficial
punctate keratopathy, followed by focal areas of
epithelial opacities.[37] Focal SEI in the anterior
stroma of the cornea appears approximately 7–
10 days following the initial involvement of the
eyes with EKC[38] (Figure 3). These opacities may
persist for years, and they may be associated
with visual disturbance, photophobia, and
astigmatism. The incidence of SEI formation
in EKC has been reported to vary from 49.1 to
80%.[39] An immunologic reaction to the replicating
adenoviruses in anterior stromal keratocytes is
hypothesized to be the underlying mechanism
for the formation of SEIs. The observation that
these opacities recur following discontinuation of
steroids supports the hypothesis.[40]
Adenovirus conjunctivitis is very contagious
and it may be transmitted up to 50% of the
time according to some reports.[41, 42] The virus
may spread through contaminated fingers, medical
devices, contaminated water at the swimming
pools, or by sharing of personal items; as many
as 46% of individuals with viral conjunctivitis
had positive viral culture grown from their hands
according to one study.[43] The adenovirus is
a very hardy organism, and it is reported to
be resistant to 70% isopropyl alcohol and 3%
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Figure 1. Adenoviral conjunctivitis presenting as bilateral watery eyes.
hydrogen peroxide.[44] The American Academy of
Ophthalmology recommends using a 1:10 dilute
bleach solution (sodium hypochlorite) to disinfect
the office equipment and instruments against
common infectious agents encountered in eye care
clinics including the adenoviruses.[45]
Due to the highly contagious nature of
viral conjunctivitis, frequent hand washing,
meticulous disinfection of medical instruments,
and isolation of conjunctivitis patients from the
rest in the healthcare provider’s office has been
recommended.[46] The incubation period for the
adenovirus is approximately 5–12 days, while the
infected individuals can transmit the disease for up
to 14 days from the time they are infected.[41]
There is no single effective treatment modality
for viral conjunctivitis; however, use of frequent
artificial tears, antihistamines containing eye
drops, or cold-compresses seem to alleviate
many of the clinical symptoms that are associated
with this condition.[47, 48] Topical and oral antiviral
medications do not appear to be useful.[47, 48]
In addition, antibiotic eye drops do not play
a role in treating viral conjunctivitis and may
even obscure the clinical picture by inducing
ocular surface toxicity.[15, 16] Other concerns
with using antibiotic drops include increased
bacterial resistance and the possibility of
spreading the disease to the contralateral eye
by cross-contamination through the infected
bottles.[42]
Membranes or pseudomembranes may be
peeled at the slit-lamp by using a pair of jeweler
forceps or cotton swab after anesthetizing the
ocular surface. This is done to alleviate patient
discomfort and prevent future scar formation.
Monotherapy against viral conjunctivitis with
Povidone-iodine 2% have been investigated in a
pilot study. The authors discovered that topical
administration of Povidone-iodine 2% four times a
day for one week led to complete resolution of the
disease in three-quarters of the eyes.[49]
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Figure 2. Pseudomembrane formation in a patient with adenoviral conjunctivitis.
The American Academy of Ophthalmology
suggests that topical corticosteroids play an
important role in the treatment of conjunctivitis, but
they should be used judiciously and with caution
in selected cases.[47] Indications for steroid usage
in viral conjunctivitis are membrane formation and
sub-epithelial infiltration associated with severe
photophobia and decreased vision. Prolonging the
duration of adenoviral conjunctivitis, exacerbation
of HSV keratitis, and an increase in intraocular
pressure are the main adverse effects of
indiscriminate use of topical corticosteroids.
Prolongation of viral shedding following
monotherapy with corticosteroids has been
reported;[50] however, combination therapies
with corticosteroids and anti-infective agents (i.e.,
antibiotics) have proven to be effective in treating
viral and bacterial conjunctivitis.[51, 52]
Ophthalmic formulations of PVP-
I/dexamethasone are widely investigated.
PVP-I 0.4%/dexamethasone 0.1% suspension,
PVP-I 1.0%/dexamethasone 0.1%, and PVP-I
0.6%/dexamethasone 0.1% have been used, and
the results suggest that the combination therapies
reduce patient symptoms and eradicate the virus
effectively.[50, 53–55]
Ongoing phase 3, randomized, double-
masked, controlled studies will further clarify
the efficacy and safety of combined PVP-
I/dexamethasone in adenoviral conjunctivitis
(ClinicalTrials.gov identifiers: NCT0299855441
and NCT0299854142) and bacterial conjunctivitis
(ClinicalTrials.gov identifiers: NCT03004924).
Use of 1 and 2% cyclosporine-A (CsA) eye drops
have been advocated for the treatment of SEIs,
and it has been demonstrated to be effective
in improving patient symptoms and reducing the
amounts of infiltrates.[30, 56] However, Jeng et al
suggested that it might be difficult to wean patients
completely off CsA once they have started it; in
their study, when CsA was stopped, SEIs returned,
necessitating reinstitution of the CsA eye drops.[57]
This finding is in contrast with the Reinhard’s pilot
study, where no recurrence was observed after
discontinuation of the CsA drops.[58] In a small
study consisting of 39 patients, administration of
1% cyclosporine-A (four times a day) during the
acute phase of viral conjunctivitis and continuing
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Figure 3. Subepithelial infiltrations in a patient with adenoviral conjunctivitis.
it thereafter for 21 days lowered the incidence of
corneal opacities significantly.[59] A case-controlled
double-blinded randomized clinical trial is needed
to investigate the effectiveness of cyclosporine-A
and to formulate an ideal tapering regiment for this
medication.
The use of topical tacrolimus eye drops has
also been investigated for the treatment of SEIs
secondary to adenoviral keratoconjunctivitis. When
tacrolimus eye drops or ointments were used for
an average of six months, a significant reduction
in the size and numbers of SEIs was observed in
60% of the cases, while in 31.76% of the eyes,
SEIs were eliminated after one year.[60] There was
also a statistically significant improvement in the
visual acuity of the patients with the use of topical
tacrolimus.
Herpetic conjunctivitis
It is estimated that 1.3–4.8% of all cases
of acute conjunctivitis are caused by HSV
infection.[61–63] HSV often causes a unilateral
follicular conjunctivitis, which may be accompanied
by a thin watery discharge and associated vesicular
lesions on the skin of the eyelids. Treatment
consists of topical antiviral agents, including
ganciclovir, idoxuridine, vidarabine, and trifluridine.
The purpose of the treatment is to reduce virus
shedding and the chance of the development of
keratitis.
Ocular involvement with herpes zoster virus,
especially when the first and second branches
of the trigeminal nerve are involved, can lead to
conjunctivitis in 41.1% of cases, eyelid lesions in
45.8%, uveitis in 38.2%, and corneal lesions such
as SEIs, pseudodendrites, and nummular keratitis
in another 19.1%.[64, 65]
Acute hemorrhagic conjunctivitis
Acute hemorrhagic conjunctivitis (AHC) is an
extremely contagious form of viral conjunctivitis.
It manifests by foreign body sensation, profuse
tearing, eyelid edema, dilatation of conjunctival
vessels, chemosis, and subconjunctival
hemorrhage. In a small proportion of patients,
fever, fatigue, and leg pain may ensue. Two
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picornaviruses, namely enterovirus 70 (EV70) and
coxsackievirus A24 variant (CA24v), as well as
certain subtypes of adenoviruses are believed
to be the responsible pathogens.[66–68] Like
the other forms of conjunctivitis, AHC is also
believed to be transmitted primarily by hand-to-
eye-to-hand contact and infected fomites.[69] The
condition is self-limited and the symptoms diminish
gradually during the first week of infection and
completely resolves after 10–14 days.[69] Medical
intervention aims primarily at controlling the large
outbreaks as well as instituting preventative
measures to protect the vulnerable groups,
such as children, elderly, pregnant women, and
immunocompromised individuals, by encouraging
frequent handwashing and reducing contact with
the affected individuals.[68]
Miscellaneous viral conjunctivitis
Infection with Molluscum contagiosum (MC) is
characterized by multiple umblicated and papular
skin lesions caused by Pox-2 virus. Skin-to-skin
contact and sexual intercourse are the main routes
of transmission. Shedding of the viral proteins
from the eyelid lesions into the tear film leads
to chronic follicular conjunctival reaction, punctate
keratopathy, and subepithelial pannus. Rarely,
primary MC lesions are found in the conjunctiva.[70]
Ebola hemorrhagic fever is a fatal disease
caused by the species of ebolavirus. Conjunctival
injection, subconjunctival hemorrhage, and tearing
have been reported in the affected individuals.[71]
Conjunctival injection, which is often bilateral and
present in up to 58% of cases, has been identified
in both the acute and late stages of this disease and
may play an important role in the early diagnosis of
this potentially deadly condition.[72] While human-
to-human transmission through bodily fluids can
spread the infection, the natural reservoir is thought
to be the fruit bat.[73]
Coronaviruses include a broad family of viruses
that normally affect animals, although some strains
can spread from animals to humans.[74] The most
recently isolated strain of coronavirus, “2019-
nCoV” , has made the headlines since it was first
recognized in December 2019 in China. COVID-19
has been reported to cause fever, cough, shortness
of breath, and even death.[75, 76] Some reports have
suggested that this virus can cause conjunctivitis
and be transmitted via the conjunctival secretions
of the infected individuals.[76] All healthcare
professionals including the ophthalmologists
should be vigilant in approaching patients with
conjunctivitis and respiratory symptoms, especially
if they report a recent history of travel to high risk
regions.[76]
Bacterial conjunctivitis
While in adults, bacterial conjunctivitis is less
common than viral conjunctivitis, in children,
it is encountered more frequently.[77] Bacterial
conjunctivitis can result from either a direct
contact with infected individuals or from abnormal
proliferation of the native conjunctival flora.[78]
Contaminated fingers,[41] oculogenital spread,[47]
and contaminated fomites[79] are common routes
of transmission. In addition, certain conditions such
as compromised tear production, disruption of the
natural epithelial barrier, abnormality of adnexal
structures, trauma, and immunosuppressed status
increase the likelihood of contracting bacterial
conjunctivitis.[47]
Acute bacterial conjunctivitis is most often
caused by Staphylococcus species, Haemophilus
influenza, Streptococcus species, Moraxella
catarrhalis, and gram-negative intestinal
bacteria.[80] In younger children, minor epidemics
may occur secondary to H. influenza or S.
pneumonia. Acute bacterial conjunctivitis
manifests by foreign body sensation and
increased ocular secretion in addition to moderate
conjunctival hyperemia (Figure 4).
Several studies on bacterial conjunctivitis[81, 82]
demonstrate that sticky eyelids and itching may
be present in approximately 90% of the affected
individuals; these findings are followed by the
less frequently encountered signs and symptoms
such as purulent secretion and ocular burning.
H. influenza conjunctivitis may be associated with
acute otitis media and upper respiratory tract
infection.[80]
In more than 60% of cases, spontaneous cure
occurs within one–two weeks,[83] and serious
complications are extremely rare.[84] However,
presence of a large population of bacteria on the
conjunctiva exposes the patient to a higher risk of
keratitis, particularly in conditions associated with
corneal epithelial defects, such as dry eye.[80]
Although topical antibiotics reduce the duration
of the disease, no difference in the outcome is seen
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between the treatment and placebo groups. In a
meta-analysis,[81], consisting of 3,673 patients from
11 randomized clinical trials, antibiotic treatment
increased the rate of clinical improvement by 10%
compared to placebo. Both “2 to 5” and “6 to
10” day regiments were included in this analysis.
Although, highly virulent bacteria can potentially
inflict serious damage to the ocular surface and the
eye,[78], no sight-threatening complications were
reported in any of the placebo groups in the
aforementioned meta-analysis.[85]
All broad-spectrum antibiotic eye drops seem to
be effective in treating bacterial conjunctivitis and
it is unlikely that there is a significant difference
among various antibiotics in achieving clinical cure.
Factors that influence antibiotic choice are local
availability, patient allergies, resistance patterns,
and cost.
From a large systematic review, it was concluded
that topical antibiotics were more effective in
achieving clinical and microbial cure when patients
had positive bacterial cultures.[21] However,
no significant difference has been reported in
clinical cure rate when different frequencies
of the antibiotics were administered.[86, 87] Due
to lengthening the course of the illness and
potentiating the infection, topical steroids should
be avoided[47] (Table 3).
Methicillin-resistant S. aureus conjunctivitis
The term methicillin-resistant S. aureus (MRSA)
refers to Staphylococcus aureus species that
are resistant to methicillin antibiotic; however,
nowadays the term is used to describe resistance
to all β-lactam antimicrobials.[88] Growing in
prevalence, 3–64% of all ocular Staphylococcus
conjunctival infections are MRSA conjunctivitis.[89]
Suspected cases need to be treated with fortified
vancomycin eye drops or ointments.[90] Culture-
directed administration of antimicrobials, effective
dosing, considering the local resistance patterns,
and appropriate antiseptic strategies should
be applied to restrict the spread of MRSA
conjunctivitis.[91]
Chlamydial conjunctivitis
Chlamydia trachomatis may cause a variety
of ocular surface infections including trachoma,
neonatal conjunctivitis, and inclusion conjunctivitis.
Serotype D-K are causative agents for neonatal
conjunctivitis and adult inclusion conjunctivitis,
while trachoma is caused by serotypes A, B, Ba,
and C.[92]
Inclusion conjunctivitis is reported to cause 1.8–
5.6% of all cases of acute conjunctivitis,[61, 62, 93]
where the majority of cases are unilateral and
have concurrent genital infection.[94] Patients
often present with mild mucopurulent discharge
and follicular conjunctivitis persisting for weeks
to months.[77] Up to 54% of men and 74% of
women are reported to have simultaneous
genital infection.[95] The disease is frequently
acquired via oculogenital spread.[47] Treatment
with systemic antibiotics such as oral azithromycin
and doxycycline is efficacious, while addition of
topical antibiotics is not beneficial. Treatment of
sexual partners and looking for the evidence of
coinfection with gonorrhea must be instituted.
As the leading cause of infectious blindness in
the world, trachoma affects 40 million individuals
worldwide; this infection is prevalent in areas with
poor hygiene. Although mucopurulent discharge
is the initial presenting sign, in the later stages,
scarring of the eyelids, conjunctiva, and cornea
may lead to loss of vision. A single dose of
oral azithromycin (20 mg/kg) in addition to oral
tetracycline or erythromycin for three weeks is
very effective. Patients may also be treated with
topical antibiotic ointments, such as tetracycline
and erythromycin, for six weeks.[96, 97]
In newborns, chlamydia can cause conjunctivitis
following passage through an infected birth canal.
The acute phase, which typically begins between
days 5 and 14 following vaginal delivery, is
characterized by purulent discharge, erythema and
edema of the eyelids and conjunctiva.[98] More
prevalent than gonococcal conjunctivitis (GC),
neonatal conjunctivitis secondary toC. trachomatis
is considered the most frequent infectious cause of
neonatal conjunctivitis worldwide.[98–100]
Although the chlamydial conjunctivitis has a mild
course, scarring of the cornea and/or conjunctiva
have been reported in untreated cases.[101] It is
important to note that up to 20% of the neonates
who are exposed to chlamydia may develop
pneumonia; in these, 50% demonstrate a previous
history of conjunctivitis.[102]
A recent meta-analysis supports the superiority
of traditional treatment with systemic erythromycin
at 50 mg/kg per day (given in four divided doses
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Table 3. Ophthalmic drug therapies for acute bacterial conjunctivitis.
Antibiotic agents Treatment
Aminoglycosides
Gentamicin Ointment: 4 ×/d for 1 wk Solution: 1-2 drops 4 ×/d for 1 wk
Tobramycin Ointment: 3 ×/d for 1 wk
Fluoroquinolones
Besifloxacin 1 drop 3 ×/d for 1 wk
Ciprofloxacin Ointment: 3 ×/d for 1 wk Solution: 1-2 drops 4 ×/d for 1 wk
Gatifloxacin 3 ×/d for 1 week
Levofloxacin 1-2 drops 4 ×/d for 1 wk
Moxifloxacin 3 ×/d for 1 wk
Ofloxacin 1-2 drops 4 ×/d for 1 wk
Macrolides
Azithromycin 2 ×/d for 2 d; then 1 drop daily for 5 d
Erythromycin 4 ×/d for 1 wk
Sulfonamides
Sulfacetamide Ointment: 4 ×/d and at bedtime for 1 wk Solution: 1-2 drops
every 2-3 h for 1 wk
Combination drops
Trimethoprim/polymyxin B 1 or 2 drops 4 ×/d for 1 wk
Figure 4. Thick purulent discharge in a patient with acute bacterial conjunctivitis.
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Figure 5. Spectrum of allergic conjunctivitis. CS, corticosteroid
Figure 6. Cobblestone appearance of large conjunctival papillae in a patient with VKC (left). Limbal VKC with Horner-Trantas dots
in another patient (right).
for two weeks), in comparison to topical antibiotic
therapy alone.[103] A recent study evaluating the
efficacy of azithromycin in neonatal chlamydial
conjunctivitis[104] demonstrated superiority of
erythromycin over azithromycin; however,
risk of pyloric stenosis related to the use of
erythromycin may reduce its clinical use in
neonates in the future.[103] Additionally, less-
frequent dose of azithromycin may improve
compliance.[105]
Gonococcal conjunctivitis (GC)
Typically viewed as a condition affecting the
neonates, GC, however, affects other age
groups as well.[106] Neisseria gonorrhoeae is a
common cause of hyperacute conjunctivitis in
neonates and sexually active adults.[78] Ocular
infection with N. gonorrhea is associated with
a high prevalence of corneal perforation.[80] GC
should be considered as the causative agent
in neonates who present with conjunctivitis in
days 2 to 5 after delivery.[106] In both neonatal
and non-neonatal populations, eye exam may
reveal conjunctival injection and chemosis
along with copious mucopurulent discharge; a
tender globe with periauricular lymphadenopathy
may also be associated with this type of
conjunctivitis.[106]
The suggested treatment for neonates include
single dose of ceftriaxone (25 to 50 mg/kg), or
cefotaxime (100 mg/kg IV or IM), in addition to
hourly saline irrigation of the ocular surface.[106–108]
Non-neonates can be treated with combination
of 1 gm of IM ceftriaxone given in a single
dose and 1 gm of oral azithromycin (which
is used to treat the frequently encountered
chlamydial coinfection). Irrigation of the ocular
surface with saline solution is not necessary in
adults.[106]
Allergic conjunctivitis
Ocular allergy can affect the entire ocular surface
including conjunctiva, eyelids, and cornea.
According to the immunological mechanism
responsible for the final clinical picture, Leonardi
et al have classified ocular allergic conditions
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Figure 7. Some systemic and dermatological conditions associated with conjunctivitis.
Figure 8. Symblepharon formation in a patient with ocular cicatricial pemphigoid.
into three main categories:[109] IgE-mediated
reactions, including seasonal allergic conjunctivitis
(SAC) and perennial allergic conjunctivitis (PAC);
combined IgE and non-IgE-mediated reactions,
including VKC and AKC; and non-IgE-mediated
reactions, including giant papillary conjunctivitis
(GPC) and contact dermatoconjunctivitis (CDC)
(Figure 5).
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Seasonal allergic conjunctivitis (SAC) and
perennial allergic conjunctivitis (PAC)
SAC and PAC are considered as themost prevalent
allergic ocular conditions, affecting 15–20% of the
population.[110] The pathogenesis is predominantly
an IgE-mediated hypersensitivity reaction, and
allergen-specific IgE antibodies are found in almost
all cases of SAC and PAC.[111] Activation of mast
cells contributes to increased levels of histamine,
prostaglandins, and leukotrienes in the tear film.
This phase, which is known as the early response
phase, clinically lasts 20–30 min.[8]
SAC, also known as hay fever conjunctivitis, is
seen in all age groups. The ocular manifestations
occur predominantly during the spring and summer
months when pollens from the trees and plants
are released into the air. PAC on the other hand
can occur throughout the year with exposure
to more common allergens such as animal hair,
mites, and feathers.[112] Clinical signs and symptoms
are similar in SAC and PAC, and include itching
and burning of the eyes, tearing, and rhinorrhea.
Corneal involvement is rarely seen.[9]
Vernal keratoconjunctivitis (VKC)
VKC is known as the disease of young males who
live in warmer climates.[113, 114] Although VKC is
frequently diagnosed in children, adults can also
be affected with this condition.[115] A mixture of IgE
and non-IgE reaction in response to nonspecific
stimuli, such as wind, dust, and sunlight is often
elucidated in this condition. Accordingly, skin
tests and serum IgE antibody tests to well-known
allergens are generally negative.[116] Both clinical
and histological findings support the concomitant
role of T-helper 2 and IgE in the pathogenesis
of VKC.[8, 117] Recently, IL-17 has been reported
to be linked to VKC, where its serum levels
can serve as a marker for the severity of the
disease.[118, 119] High percentage of antinuclear
antibodies (ANA) positivity and family history
of autoimmune disorders in patients with VKC
suggests a strong link between this condition
and other autoimmune disorders including
atopy.[120, 121]
Typical seasonal patterns as well as perennial
forms have been reported in patients affected
with VKC.[122] Presence of papillary hyperplasia is
essential for the diagnosis of VKC, and its presence
allows for the differentiation of VKC from other
related entities such as SAC and PAC.[123]
Conjunctival injection, profuse tearing, severe
itching, and photophobia are the main clinical
signs and symptoms that are associated with VKC.
There are three clinical forms of VKC that include
limbal, palpebral, and mixed type.[112] Limbal type
is characterized by limbal papillary reaction and
gelatinous thickening of the limbus; when the
disease is active, Horner-Trantas dots are usually
present at the superior limbal margins.[112] The
hallmark of the palpebral VKC is the presence
of giant papillae, with consequent cobblestone
appearance. The mixed type has the features of
palpebral and limbal VKC simultaneously (Figure 6).
The corneal pathology that is seen in VKC is
partly caused by the mechanical trauma from the
tarsal conjunctival papillae and the inflammatory
responses secondary to the release of cytokines.
The inflammatory mediators are believed to be
released by the eosinophils and mast cells that
are infiltrated into the conjunctival tissue.[124, 125]
In up to 6% of patients, corneal ulcers (i.e.,
shields ulcer) and plaques may develop, leading
to the exacerbation of the clinical symptoms and
worsening of the vision.[126, 127] These ulcers are
usually found as oval lesions with elevated margins
surrounding a chronic epithelial defect covered by
eosinophilic and epithelial debris in the upper parts
of the cornea.[128] Keratoconus is another entity that
is highly associated with VKC affecting nearly 15%
of the patients with this condition.[129]
Atopic keratoconjunctivitis (AKC)
AKC is characterized by chronic allergic disease of
the eyelid, cornea, and conjunctiva. It is considered
the ocular component of atopic dermatitis (AD),
and roughly 95% of the patients with AKC have
concomitant AD;[8, 11] however, less than half of
patients with AD have involvement of their ocular
tissue.[130] Many cytokines are released from the
epithelial cells of the conjunctiva as well as
the inflammatory cells that have infiltrated the
conjunctival tissues in AKC. This causes constant
remodeling of the ocular surface connective tissue
leading to mucus metaplasia, scar formation, and
corneal neovascularization.[131]
AKC is typically diagnosed in the second and
third decades of life, although scattered cases are
seen in the early childhood as well as in the fifth
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decade of life.[132] Age of the onset, duration of
the disease, and clinical presentations may help
clinicians to distinguish this condition from VKC.[132]
Clinical manifestation of AKC includes
epiphora, itching, redness, and decreased
vision. Presentation is often bilateral; however,
unilateral disease has been reported.[133]
The eyelid skin may be edematous with a
sandpaper-like texture. Conjunctival injection
and chemosis range from mild to severe, and
conjunctival scarring is common.[11] Trantas
dots and giant papillae may or may not be
present. In contrast to VKC, AKC is associated with
conjunctival fibrosis and corneal vascularization
and opacities. An early cataract surgery is not
uncommon in AKC patients, as this condition is
associated with formation of “atopic cataracts”
at a relatively young age. Shield-like cataracts,
as well as nuclear, cortical and even posterior
subcapsular cataracts may also occur. Nearly
50% of AKC patients test negative for common
allergens.[8]
Giant papillary conjunctivitis (GPC)
Similar to vernal conjunctivitis, GPC is
characterized by papillary hypertrophy of the
superior tarsal conjunctiva.[134] Although GPC
is primarily considered as a complication of
contact lens usage, this condition has also been
reported in association with corneal foreign
bodies, filtering blebs, ocular prostheses,
exposed sutures, limbal dermoids, and tissue
adhesives.[135–137] The classic signs of GPC consist
of excessive mucous secretion associated with
decreased contact lens tolerance.[137] Mast cells
and eosinophils may be found in the conjunctiva;
however, there are no increases in the levels of
IgE or histamines in the tears of patients with
GPC.[8]
GPC can occur with both hydrogel and
rigid contact lenses, and it has been reported
with either hydroxyethyl methacrylate (HEMA),
silicone polymers, or the new gas permeable
polymers.[134] However, it is less frequent with
rigid contact lenses. Mechanical injuries due to
contact lens wear and inflammatory reactions
secondary to surface proteins of the lens
can contribute to the chronic inflammatory
damage of the ocular surface[110, 138] seen in
this condition.
Contact allergy
CDC is a classic example of type-IV delayed
hypersensitivity reaction that occurs through
interaction of antigens with T cells followed by
release of cytokines.[139] Low molecular weight
allergens combine with host proteins to form
the final allergens capable of exerting immune
response. Some of the known allergens for CDC
include poison ivy, poison oak, neomycin, nickel,
latex, atropine and its derivatives.[8] Primary
sensitization phase describes the process through
which memory T cells derive from resident T cells
of the ocular tissue, while the following elicitation
phase includes the interaction between these
memory cells and allergens.[8] IL-17-producing Th
cells and regulatory T cells also play a role in the
pathogenesis of CDC.[140]
Similar to AKC, contact allergy involves the
conjunctiva, cornea, and eyelids. The condition
may be associated with itching, lid swelling,
follicular reaction, and even cicatrization in later
stages of the disease. The corneal involvement
may be in the form of punctate keratitis,
pseudodendritic keratitis, and grayish stromal
infiltrates.[112, 141]
Treatment
Avoidance of the allergens is the main stay of
treatment for many forms of allergies including
allergic conjunctivitis. Artificial tears provide a
barrier function, dilute various allergens, and flush
the ocular surface clean from many inflammatory
mediators.
The treatment options for allergic conjunctivitis
include lubricating eye drops, anti-histamines,
and mast cell stabilizers.[142, 143] Many studies
have demonstrated the superiority of topical
antihistamines and mast cell stabilizers compared
to placebo in alleviating the symptoms of
allergic conjunctivitis; in addition, it has been
demonstrated that antihistamines are more
beneficial than mast cell stabilizers for providing
short-term relief.[144] Several eye drop preparations
with dual action (antihistamine and mast cell-
stabilizing effects) including olopatadine, ketotifen,
azelastine, and epinastine have been introduced
to market in the recent years. These agents
can provide simultaneous histamine receptor
antagonist effects, stabilize mast-cell membranes,
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and modify the action of eosinophils.[145]
Mast cell stabilizers require a loading period
of several weeks, and therefore, they are
better to be administered before the antigen
exposure.
Oral antihistamines are commonly used for
alleviating the ocular symptoms in patients
with allergic conjunctivitis. Second generation
antihistamines are preferred due to their fewer
adverse systemic side effects.[146] Unfortunately,
oral antihistamines induce ocular drying, which
can significantly worsen the symptoms of allergic
conjunctivitis.[147]
Steroids should be used judiciously and only
in selected cases. Topical and oral administration,
in addition to supratarsal injections are often
required if the condition is severe; unfortunately,
any route of corticosteroid administration is
associated with formation of cataracts and
elevated intraocular pressure.[112] Non-steroidal
anti-inflammatory drugs such as ketorolac
and diclofenac can also be added to the
treatment regimen to provide additional benefits.
Moreover, other steroid-sparing agents such
as cyclosporine-A and tacrolimus are effective
in treating severe and chronic forms of ocular
allergies.
Allergen-specific immunotherapy, which has
gained popularity in the recent years, works
by inducing clinical tolerance to a specific
allergen. This appears to be an effective
treatment options for those with allergic
rhinoconjunctivitis who demonstrate specific
IgE antibodies.[148] Traditionally, immunotherapy
is performed via subcutaneous injections;
however, sublingual immunotherapy (SLIT)
has drawn the attention among allergists
as an alternative. SLIT has been shown to
effectively reduce the ocular and nasal signs
and symptoms of allergic conjunctivitis, with
a greater benefit toward improving the nasal
symptoms.[112]
Conjunctivitis associated with systemic
diseases
Conjunctivitis may be the initial presentation for
many systemic diseases; therefore, a thorough
history and systemic evaluation in selected cases
may help in early diagnosis of many potentially
disabling and even life-threatening conditions. A
summary of systemic diseases associated with
conjunctivitis is provided in Figure 7.
Reactive arthritis
Conjunctivitis is one of the most common
ocular manifestations of reactive arthritis;
other associated ocular entities include uveitis,
episcleritis, scleritis, and keratitis.[149] Conjunctivitis
in reactive arthritis entities manifests itself as
conjunctival hyperemia with purulent discharge.
Occurring in nearly one third of the patients,
conjunctivitis is an essential component of the
“Reiter’s triad”.[150] Conjunctivitis usually happens
early in the course of reactive arthritis and it may
even precede it in some instances; given its mild
initial clinical presentation, it is often missed. The
signs and symptoms usually abate within one to
four weeks; however, in some cases, progression
to more severe ocular surface problems may
ensue.[151]
Rosacea
Ocular surface may also be involved in
the inflammatory course of ocular rosacea.
The clinical findings include a follicular and
papillary conjunctival reaction in association
with interpalpebral conjunctival hyperemia. In
addition, cicatrization of the conjunctival tissue,
mimicking trachoma, may be seen in these
patients. Conjunctival scarring secondary to
entropion and trichiasis has been reported
to occur in approximately 10% of the cases.
Conjunctival granuloma, pinguecula, phlyctenule,
and peripheral corneal infiltration and phlyctenule
are amongst some of the other findings associated
with ocular rosacea.[152]
Graft-versus-host disease
Conjunctival involvement is rarely seen in acute
graft-versus-host disease (GVHD); however,
its presence indicates more severe systemic
involvement and a poor prognosis. Conjunctival
involvement in GVHD ranges from mild
conjunctival injection to pseudomembranous
and cicatrizing conjunctivitis.[153, 154] In acute
GVHD, conjunctivitis is often ulcerative and
manifests itself with numerous alternating
episodes of conjunctival hemorrhage and
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exudative discharge. Sterile purulent discharge,
pseudomembrane formation, and scarring
are amongst the other findings in this
condition.[153] In the chronic form of GVHD,
one-fourth to three-fourth of the patients suffer
from dry eyes, where its severity correlates
with the severity of GVHD.[155] Frequently,
keratoconjunctivitis sicca persists after remission
of GVHD.[156]
Four stages of conjunctival GVHD have been
described in the literature. Stage 1 is marked
by simple conjunctival injection. Stage 2 is
characterized by an exudative response, which
may lead to conjunctival chemosis. Stage 3 is
characterized by pseudomembrane formation;
majority of the patients are diagnosed at this
stage of the diseases. Stage 4 is manifested
by scarring and cicatrization of the conjunctival
tissue.[153, 156]
Ocular cicatricial pemphigoid
Ocular cicatricial pemphigoid is a rare
condition. Patients are often in their fifth and
sixth decades of life at presentation, and
females are up to three times more frequently
affected than males.[157] Chronic inflammation,
loss of conjunctival goblet cells along with
an abnormal mucosal epithelial turn-over
leads to desiccation of the ocular surface
in this condition[158] (Figure 8). Disruption
of conjunctival immune network increases
the risk of ocular surface infection.[158]
Recurrent infectious conjunctivitis and trichiasis
may lead to keratinization of the surface
epithelium.[158] Definitive diagnosis requires
direct immunofluorescence, where deposits
of immunoglobulins and/or complements
produce areas of linear hyperfluorescence at
the epithelial basement membrane. Systemic
immunosuppression along with frequent
lubrication is often needed to adequately control
this condition.
Stevens-Johnson syndrome and toxic
epidermal necrolysis
Ophthalmic manifestations of the acute stages
of Stevens-Johnson syndrome (SJS) and toxic
epidermal necrolysis (TEN) range from conjunctival
hyperemia to near-complete sloughing of palpebral
conjunctiva and lid margins.[159] Acute ocular
involvement is reported to occur in up to 88% of the
cases.[159] It remains unclear whether the severity
of ocular involvement is any different between SJS
and TEN.[160] Long-term adverse consequences
following the acute stage of ocular surface disease
include severe dry eyes, symblepharon formation,
corneal limbal stem cell deficiency, and corneal
scarring.[160]
Toxic conjunctivitis
It has been recently realized that long-term
use of topical eye medications may induce
ocular surface changes including dry eyes,
conjunctival inflammation, ocular surface fibrosis,
and scarring.[161, 162] Another area where the side
effects of topical eye drops cause significant
ocular morbidity is their use in glaucoma and
in patients who have undergone glaucoma
surgery. Subclinical infiltration of the conjunctival
epithelium and substantia propria by inflammatory
cells has also been reported.[163, 164] The published
literature during the past decade has pointed to
the deleterious effects of benzalkonium chloride
(BAK), which is used as a preservative in eye drops,
on the ocular surface.[165]
Allergic reactions are the most clinically
noticeable side effect of the eye drops; however,
they are far less frequent and harmful than
their adverse toxic side effects.[166] The allergic
reaction to eye drops includes simple conjunctival
congestion, papillary conjunctivitis, and GPC.[165]
The signs and symptoms usually manifest a few
days after starting the offending eye drop and
tend to resolve quickly when the medication is
stopped.[166]
Observational studies have confirmed the high
prevalence of dry eyes in glaucomapatients related
to the number of eye drops being used. This ranges
from 11% in those who use only one eye drop
to 43% in those who use two or three different
eye drops.[167] Similarly, a cross-sectional study
evaluating the ocular surface in 101 patients being
treated for glaucoma reported that approximately
60% of them were symptomatic in at least one
eye.[168] In a survey performed on 300 patients
in the US between 2001 and 2004, adverse side
effects were reported to be the second most
common reason for switching eye drops.[169]
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Increase in fibroblast density in the conjunctiva,
and development of subconjunctival fibrosis
has been reported in patients who use
antiglaucoma drops chronically.[165] In a series of
145 patients, Thorne et al reported that exposure
to antiglaucoma eye drops was the primary reason
for development of pseudopemphigoid.[170]
Despite the indisputable data and the findings
from multiple observational studies on the
harmful side effects of BAK, it is still used as
the main preservative ingredient in most eye drop
preparations due to lack of a better alternative.[165]
Limiting the exposure to preservatives may
diminish the toxic side effects of eye drops; this will
likely lead to higher patient compliance and result
in a more favorable clinical outcome, especially
in those who need to be on antiglaucoma
medications.
Summary
Approximately 1% of all patient visits to their
primary care physician is conjunctivitis related,
and the estimated cost of infectious conjunctivitis
to the healthcare is more than $800 million
annually in the US alone.[2] The first step in
approaching a patient with presumed conjunctivitis
is to rule out serious ocular conditions that present
with “red eye”, mimicking conjunctivitis. This
must be done with obtaining a thorough history
and performing a detailed ophthalmologic and
physical examination. Ancillary laboratory testing
and imaging are also important components of
evaluating these patients. Various studies have
demonstrated that obtaining a thorough history is
essential to narrow down the differential diagnosis
and discover the underlying etiology for the
conjunctivitis, while relying solely on the presenting
signs and symptoms can be misleading and often
leads to an inaccurate diagnosis. Viral conjunctivitis
followed by bacterial conjunctivitis are the most
common causes of infectious conjunctivitis.[15, 25, 81]
The majority of viral conjunctivitis cases are
due to adenoviruses,[28] and the use of rapid
antigen test to diagnose adenoviral conjunctivitis
may present an appropriate strategy to avoid
overuse of antibiotics. Bacterial pathogens are
isolated in half of the cases of conjunctivitis,[61]
and approximately 60% of culture-positive cases
are known to be self-limited.[80] Cultures should
be obtained from the conjunctival swabs of
patients that do not respond to therapy, and
those suspected to have chlamydial infection
and hyperacute conjunctivitis.[47] Treatment with
topical antibiotics is usually recommended for
suspected cases of chlamydial and gonococcal
conjunctivitis and contact lens wearers.[61, 80] The
majority of cases of allergic conjunctivitis are due
to seasonal allergies. Antihistamines and mast cell
stabilizers are widely used for treating allergic
conjunctivitis. Steroids must be used judiciously
and only when indicated. For patients with chronic
conjunctivitis, possibility of systemic diseases and
adverse effects of eye drops with preservatives
should be kept in mind.
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